Last mentioned: Feb 27, 2026
TGA Approval
Australian regulators approve the Virtual Nodule Clinic for clinical use.
Series A Funding
Company raises $14M to scale global commercial operations.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for lung cancer AI.
The Australian government is significantly reducing funding for expensive spinal cord stimulators following reports linking the devices to severe patient injuries. This regulatory shift follows a clinical review that found the high-cost implants often provide no long-term benefit over conservative care.
Optellum has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. This expansion allows Australian clinicians to utilize advanced imaging analytics to improve early lung cancer detection and streamline patient care pathways.